

# 18th August 2023

# SOMNOMED 2023 FULL-YEAR FINANCIAL RESULTS INVESTOR CONFERENCE CALL

**SomnoMed Limited (ASX SOM, or the Company)** advises its FY2023 Financial Results and Investor Presentation will now be released to the ASX after the market closes on 29<sup>th</sup> August 2023. This date has changed from 24<sup>th</sup> August 2023.

Following the release, management will host an investor conference call and webcast including a Q&A session. Participants are encouraged to register before the start of the call using the details below.

Date: Tuesday, 29th August 2023

Time: 4:30pm (Australian Eastern Standard Time)

### Webcast Link:

The audio webcast and slide presentation registration will be accessible via the following link:

https://ccmediaframe.com/?id=f7wDCqPt

#### **Dial In Details:**

Investors wishing to ask questions will be required to register and dial-in via the following link:

https://s1.c-conf.com/diamondpass/10031182-ayhrf8.html

Once you have registered you will receive an email confirming your attendance with a dial-in number as well as a conference access code and unique PIN number that you must enter to access the call or submit any questions.

#### This release has been approved by the Board of SomnoMed Limited

## For further information please contact

| Corporate                   | Investors                        |
|-----------------------------|----------------------------------|
| Mr. Neil Verdal-Austin      | Mr. Howard Marks                 |
| CEO SomnoMed                | Automic Markets                  |
| +61 406 931 477             | +61 402 438 019                  |
| Nverdal-austin@somnomed.com | Howard.marks@automicgroup.com.au |

#### **About SomnoMed**

SomnoMed is a public company providing treatment solutions for sleep-related breathing disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent® becoming the state-of-the-art and clinically proven medical oral appliance therapy for more than 810 000 patients in 28 countries. For additional information, visit SomnoMed at <a href="http://www.somnomed.com.au">http://www.somnomed.com.au</a>